Investor Relations

Press Releases

10/04/21
Conformis, Inc. to Release Third Quarter 2021 Financial Results on November 3, 2021
BILLERICA, Mass. , Oct. 04, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS) announced today that it will release its financial results for the third quarter ended September 30, 2021 after the market closes on November 3, 2021 at approximately 4:00 p.m. Eastern Time .
09/29/21
Conformis, Inc. Announces Strong Clinical Study Results for Its Personalized Knee Implants
A retrospective review of 540 procedures performed demonstrated 98.5% Implant Survivorship and 89.0% Patient Satisfaction for the Conformis patient-specific iTotal® CR (cruciate-retaining) knee replacement implants at mid-term follow-up BILLERICA, Mass. , Sept.
09/20/21
Conformis, Inc. Provides Business Update
Business Update Provided in Advance of the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit BILLERICA, Mass. , Sept. 20, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) provided today an update of its third quarter revenue performance expectations in advance of the Oppenheimer Fall
09/07/21
Conformis, Inc. to Participate in Upcoming Investor Conferences
BILLERICA, Mass. , Sept. 07, 2021 (GLOBE NEWSWIRE) -- Conformis , Inc. (NASDAQ: CFMS), an orthopedic medical device company that features a range of personalized knee and hip replacement products, announced today that Mark Augusti , Chief Executive Officer, and Bob Howe , Chief Financial Officer,
08/18/21
Conformis, Inc. Announces First Procedure Performed Using the Identity Imprint™ Knee Replacement System
BILLERICA, Mass. , Aug. 18, 2021 (GLOBE NEWSWIRE) -- Conformis , Inc. (NASDAQ:CFMS) today announced the first procedure with the new Conformis Identity Imprint knee replacement system. Identity Imprint, available in both cruciate retaining (CR) and posterior stabilized (PS) implants, utilizes a
08/04/21
Conformis Reports Second Quarter 2021 Financial Results
BILLERICA, Mass. , Aug. 04, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the second quarter ended June 30, 2021 .
07/14/21
Conformis, Inc. to Present at the Canaccord Genuity 40th Annual Growth Conference
BILLERICA, Mass. , July 14, 2021 (GLOBE NEWSWIRE) -- Conformis , Inc. (NASDAQ: CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today that Mark Augusti , Chief Executive Officer, and Bob Howe , Chief Financial Officer, will present
07/07/21
Conformis, Inc. Announces Settlement of Wright Medical Patent Litigation
Conformis Settles Wright Medical Litigation Related to Patient-Specific Instruments for Use with Shoulder Implants BILLERICA, Mass. , July 07, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that it has entered into a settlement with Stryker Corporation (“Stryker”) resolving
07/01/21
Conformis, Inc. to Release Second Quarter 2021 Financial Results on August 4, 2021
BILLERICA, Mass. , July 01, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS) announced today that it will release its financial results for the second quarter ended June 30, 2021 after the market closes on August 4, 2021 at approximately 4:00 p.m. Eastern Time .
06/23/21
Conformis, Inc. Announces Exclusive Distribution Agreement in China
New Agreement expands Conformis’ global reach and brings patient-specific knee replacement systems to the largest market in the Asia-Pacific region BILLERICA, Mass. , June 23, 2021 (GLOBE NEWSWIRE) -- Conformis , Inc. (NASDAQ:CFMS) today announced the execution of an agreement to enter the
05/18/21
Conformis, Inc. to Present at the Oppenheimer MedTech, Tools & Diagnostics Summit
BILLERICA, Mass. , May 18, 2021 (GLOBE NEWSWIRE) -- Conformis , Inc. (NASDAQ: CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today that Mark Augusti , Chief Executive Officer, will present at the Oppenheimer MedTech, Tools &
05/12/21
Conformis, Inc. to Present at the Canaccord Genuity Musculoskeletal Conference
BILLERICA, Mass. , May 12, 2021 (GLOBE NEWSWIRE) -- Conformis , Inc. (NASDAQ: CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today that Mark Augusti , Chief Executive Officer, and Bob Howe , Chief Financial Officer, will present
05/10/21
Conformis, Inc. Announces 510(k) Clearance for Identity Imprint™ Knee Replacement System
Leveraging Conformis’ extensive library of personalized knee design data and patient images, Identity Imprint is designed to match patients’ anatomy with an optimal arthroplasty solution while at the same time offering greater efficiency, cost savings, increased intraoperative flexibility, and
05/05/21
Conformis Reports First Quarter 2021 Financial Results
BILLERICA, Mass. , May 05, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the first quarter ended March 31, 2021 .
04/22/21
Conformis Announces Achievement of Third Milestone Under Development and License Agreements
BILLERICA, Mass. , April 22, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that it received 510(k) clearance by the U.S. Food and Drug Administration for patient-specific instrumentation (“PSI”) developed by the Company under its License Agreement and Development Agreement
04/19/21
Conformis Announces License Agreement with Paragon 28
Commercial Interest in Accurate, Disposable, Patient-Specific Instrumentation Continues to Expand BILLERICA, Mass. , April 19, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that it has entered into a license agreement with Paragon 28, Inc., granting Paragon 28 a
04/07/21
Conformis, Inc. to Release First Quarter 2021 Financial Results on May 5, 2021
BILLERICA, Mass. , April 07, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS) announced today that it will release its financial results for the first quarter ended March 31, 2021 after the market closes on May 5, 2021 at approximately 4:00 p.m. Eastern Time .
03/16/21
Clinical Study: Patient-Specific Total Knee Replacement with Conformis Technology Is More Cost-Effective Than with Leading Off-the-Shelf Implants
Independent, retrospective review of 2016-2019 surgeon data by University of Washington researchers demonstrates that Conformis iTotal® knee replacement implants enable expedited surgical time and reduce length of hospital stay. BILLERICA, Mass. , March 16, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc.
03/03/21
Conformis, Inc. Reports Fourth Quarter and Year End 2020 Financial Results
BILLERICA, Mass. , March 03, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today financial results for the fourth quarter and year ended December 31, 2020 . Fourth Quarter 2020 Summary Total revenue of $16.7 million , a decrease of 16% year-over-year on a reported basis and 17%
03/01/21
Conformis, Inc. Announces Clearance in Australia for iTotal® PS, the Only Personalized, Posterior-Stabilized Total Knee Replacement System
The iTotal® PS total knee replacement system is designed so that its patient-specific implants fit the unique size and shape of each patient’s knee, and provide optimal stability throughout the full range of motion BILLERICA, Mass. , March 01, 2021 (GLOBE NEWSWIRE) -- Conformis , Inc. (NASDAQ:
02/25/21
Conformis, Inc. to Participate in Upcoming Investor Conferences
BILLERICA, Mass. , Feb. 25, 2021 (GLOBE NEWSWIRE) -- Conformis , Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today that Mark Augusti , Chief Executive Officer, and Bob Howe , Chief Financial Officer, will participate
02/12/21
Conformis, Inc. Announces Pricing of $85 Million Underwritten Offering of Common Stock
BILLERICA, Mass. , Feb. 12, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (Nasdaq: CFMS) today announced it has priced an underwritten public offering of 80,952,381 shares of its common stock at an offering price of $1.05 per share. The gross proceeds from the offering will be approximately $85 million
02/11/21
Conformis, Inc. Announces Proposed Public Offering of Common Stock
BILLERICA, Mass. , Feb. 11, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (Nasdaq: CFMS) today announced that it intends to offer shares of its common stock in an underwritten public offering. Conformis intends to grant the underwriters a 30-day option to purchase additional shares of its common stock
01/21/21
Conformis, Inc. and SITES Medical Announce Development & Supply Agreement
BILLERICA, Mass. and COLUMBIA CITY, Ind. , Jan. 21, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) and SITES Medical, a firm dedicated to inventing and de-risking new orthopedic medical device technologies, today announced they have entered into a non-exclusive development and supply
01/07/21
Conformis, Inc. to Release Fourth Quarter and Fiscal Year 2020 Financial Results on March 3, 2021
BILLERICA, Mass. , Jan. 07, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS) announced today that it will release its financial results for the fourth quarter and fiscal year ended December 31, 2020 after the market closes on March 3, 2021 at approximately 4:00 p.m. Eastern Time .